Lu and colleagues identify BRD4 as a central epigenetic driver of vesicant-induced corneal injury. Using reproducible mouse and rabbit models, they show that short-term topical BRD4 inhibition suppresses acute inflammation and provides durable protection of corneal clarity, stromal organization, endothelial integrity, and neovascularization, supporting translational therapy for chemical eye injuries.